keyword
MENU ▼
Read by QxMD icon Read
search

Rheumatoid arthritis treatment

keyword
https://www.readbyqxmd.com/read/28230210/synergistic-suppression-of-autoimmune-arthritis-through-concurrent-treatment-with-tolerogenic-dc-and-msc
#1
Rong Li, Yujuan Zhang, Xiufen Zheng, Shanshan Peng, Keng Yuan, Xusheng Zhang, Weiping Min
Rheumatoid arthritis (RA) is an autoimmune disease characterized by progressive immune-mediated joint deterioration. Current treatments are not antigen specific and are associated with various adverse. We have previously demonstrated that tolerogenic dendritic cells (Tol-DC) are potent antigen-specific immune regulators, which hold great promise in immunotherapy of autoimmune diseases. In this study, we aimed to develop new immunotherapy by combining Tol-DC and mesenchymal stem cells (MSC). We demonstrated that RelB gene silencing resulted in generation of Tol-DC that suppressed T cell responses and selectively promoted Treg generation...
February 23, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28228278/immunopathogenesis-of-rheumatoid-arthritis
#2
REVIEW
Gary S Firestein, Iain B McInnes
Rheumatoid arthritis (RA) is the most common inflammatory arthropathy. The majority of evidence, derived from genetics, tissue analyses, models, and clinical studies, points to an immune-mediated etiology associated with stromal tissue dysregulation that together propogate chronic inflammation and articular destruction. A pre-RA phase lasting months to years may be characterized by the presence of circulating autoantibodies, increasing concentration and range of inflammatory cytokines and chemokines, and altered metabolism...
February 21, 2017: Immunity
https://www.readbyqxmd.com/read/28227413/segmentation-of-the-metacarpus-and-phalange-in-musculoskeletal-ultrasound-images-using-local-active-contours
#3
Nelson Martins, Malik Saad Sultan, Diana Veiga, Manuel Ferreira, Miguel Coimbra, Nelson Martins, Malik Saad Sultan, Diana Veiga, Manuel Ferreira, Miguel Coimbra, Diana Veiga, Nelson Martins, Malik Saad Sultan, Miguel Coimbra, Manuel Ferreira
This work presents a method for the automatic segmentation of metacarpus and phalange bones in ultrasound images of the second metacarpophalangeal joint (MCPJ) using Active Contours. The MCPJ is known to be the one of the first structures to be affected by rheumatic diseases like rheumatoid arthritis. The early detection and follow-up of this disease is important to prevent irreversible damage of the joints, which occurs continuously and faster if no treatment is used. To our knowledge, there is no automatic system to quantify the extension of the lesions resulting from rheumatic activity...
August 2016: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/28225768/anti-rheumatic-treatment-is-not-associated-with-reduction-of-pentraxin-3-in-rheumatoid-arthritis-psoriatic-arthritis-and-ankylosing-spondylitis
#4
Gia Deyab, Ingrid Hokstad, Jon Elling Whist, Milada Cvancarova Småstuen, Stefan Agewall, Torstein Lyberg, Barbara Bottazzi, Pier Luigi Meroni, Roberto Leone, Gunnbjorg Hjeltnes, Ivana Hollan
BACKGROUND: Pentraxin 3 is proposed to be a marker of inflammation and cardiovascular risk, but its role in inflammatory rheumatic diseases (IRDs) is still uncertain. Therefore, we wanted to examine if anti-rheumatic treatment reduced serum PTX3 (s-PTX3) levels in IRDs, and if s-PTX3 levels were related to other markers of inflammation and to endothelial function (EF). METHODS: We examined s-PTX3, EF and established inflammatory biomarkers in 114 IRD patients from the PSARA study before and after 6 weeks and 6 months of treatment with methotrexate (MTX) or anti-tumor necrosis factor alpha (anti-TNF) therapy with or without MTX co-medication...
2017: PloS One
https://www.readbyqxmd.com/read/28224284/complementary-and-alternative-medicine-use-in-rheumatoid-arthritis-considerations-for-the-pharmacological-management-of-elderly-patients
#5
REVIEW
Sizheng Zhao, Fred Otieno, Asan Akpan, Robert J Moots
Complementary and alternative medicines (CAMs) are widely used by patients with rheumatoid arthritis (RA); however, a significant proportion of these patients do not inform their physicians. This has many potential implications in a group of predominantly elderly patients with altered pharmacokinetics, comorbidities and polypharmacy of potentially toxic drugs. CAM usage may affect compliance and pharmacokinetics of conventional therapy for RA and comorbidities; therefore, physicians should engage patients in dialogues regarding CAM usage...
February 21, 2017: Drugs & Aging
https://www.readbyqxmd.com/read/28223750/tumor-necrosis-factor-alpha-blocker-induced-erythrodermic-sarcoidosis-in-with-juvenile-rheumatoid-arthritis-a-case-report-and-review-of-the-literature
#6
Su-Kyung Park, Pyung-Han Hwang, Seok-Kweon Yun, Han-Uk Kim, Jin Park
The development of cutaneous sarcoidosis as a paradoxical adverse event of tumor necrosis factor alpha (TNF-α) blockers has been reported in the literature; however, an erythrodermic form of cutaneous sarcoidosis during anti-TNF-α therapy has not yet been reported. Herein, we report the first case of an erythrodermic form of cutaneous sarcoidosis during anti-TNF-α therapy and review previous studies of cutaneous sarcoidosis. A 6-year-old Korean girl who had been suffering from juvenile rheumatoid arthritis presented with generalized erythematous skin eruption involving more than about 90% of her body surface area...
February 2017: Annals of Dermatology
https://www.readbyqxmd.com/read/28223263/apps-for-people-with-rheumatoid-arthritis-to-monitor-their-disease-activity-a-review-of-apps-for-best-practice-and-quality
#7
Rebecca Grainger, Hermaleigh Townsley, Bonnie White, Tobias Langlotz, William J Taylor
BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory arthritis requiring long-term treatment with regular monitoring by a rheumatologist to achieve good health outcomes. Since people with RA may wish to monitor their own disease activity with a smartphone app, it is important to understand the functions and quality of apps for this purpose. OBJECTIVE: The aim of our study was to assess the features and quality of apps to assist people to monitor their RA disease activity by (1) summarizing the available apps, particularly the instruments used for measurement of RA disease activity; (2) comparing the app features with American College of Rheumatology and European League against Rheumatism (ACR and EULAR) guidelines for monitoring of RA disease activity; and (3) rating app quality with the Mobile App Rating Scale (MARS)...
February 21, 2017: JMIR MHealth and UHealth
https://www.readbyqxmd.com/read/28223071/therapeutic-antibody-targeting-of-indoleamine-2-3-dioxygenase-ido2-inhibits-autoimmune-arthritis
#8
Lauren M F Merlo, Samantha Grabler, James B DuHadaway, Elizabeth Pigott, Kaylend Manley, George C Prendergast, Lisa D Laury-Kleintop, Laura Mandik-Nayak
Rheumatoid arthritis (RA) is a debilitating inflammatory autoimmune disease with no known cure. Recently, we identified the immunomodulatory enzyme indoleamine-2,3-dioxygenase 2 (IDO2) as an essential mediator of autoreactive B and T cell responses driving RA. However, therapeutically targeting IDO2 has been challenging given the lack of small molecules that specifically inhibit IDO2 without also affecting the closely related IDO1. In this study, we develop a novel monoclonal antibody (mAb)-based approach to therapeutically target IDO2...
February 18, 2017: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/28222785/tcd4-pos-lymphocytosis-in-rheumatoid-and-psoriatic-arthritis-patients-following-tnf%C3%AE-blocking-agents
#9
Andrea Picchianti Diamanti, Bruno Laganà, Maria Christina Cox, Emanuela Pilozzi, Rachele Amodeo, Maurizio Bove, Milica Markovic, Roberta Di Rosa, Simonetta Salemi, Maria Laura Sorgi, Maria Manuela Rosado, Raffaele D'Amelio
BACKGROUND: Lymphocyte expansion and true lymphocytosis are commonly observed in the everyday clinical practice. The meaning of such phenomenon is often poorly understood so that discrimination between benign and malignant lymphocytosis remains difficult to establish. This is mainly true when lymphocytosis rises in patients affected by immune-mediated chronic inflammatory diseases under immunosuppressive treatment, conditions potentially associated with lymphomagenesis. In this brief report the development of mild T CD4(pos) lymphocytosis in a group of patients with chronic arthritis under anti-TNF-α treatment is described...
February 21, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28221313/systematic-review-and-meta-analysis-of-interventions-for-depression-and-anxiety-in-persons-with-rheumatoid-arthritis
#10
Kirsten M Fiest, Carol A Hitchon, Charles N Bernstein, Christine A Peschken, John R Walker, Lesley A Graff, Ryan Zarychanski, Ahmed Abou-Setta, Scott B Patten, Jitender Sareen, James Bolton, Ruth Ann Marrie
BACKGROUND: Psychiatric comorbidities, such as depression and anxiety, are very common in persons with rheumatoid arthritis (RA) and can lead to adverse outcomes. By appropriately treating these comorbidities, disease-specific outcomes and quality of life may be improved. OBJECTIVE: The aim of this study was to systematically review the literature from controlled trials of treatments for depression and anxiety in persons with RA. METHODS: We searched multiple online databases from inception until March 25, 2015, without restrictions on language, date, or location of publication...
February 17, 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/28217871/secukinumab-in-active-rheumatoid-arthritis-a-randomized-double-blind-placebo-and-active-comparator-controlled-phase-3-study
#11
Francisco J Blanco, Rüdiger Möricke, Eva Dokoupilova, Christine Codding, Jeffrey Neal, Mats Andersson, Susanne Rohrer, Hanno Richards
OBJECTIVE: To evaluate the efficacy and safety of secukinumab in patients with active rheumatoid arthritis (RA) who had an inadequate response or intolerance to tumor necrosis factor inhibitors (TNF-inhibitors). METHODS: In this phase 3 study, 551 patients were randomized (1:1:1:1) to receive intravenous secukinumab 10 mg/kg (baseline, weeks 2, 4) followed by subcutaneous secukinumab 150 mg or 75 mg every 4 weeks or abatacept or placebo at the same dosing schedule...
February 19, 2017: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/28216754/transfibular-ankle-arthrodesis-a-novel-method-for-ankle-fusion-a-short-term-retrospective-study
#12
S Muthukumar Balaji, V Selvaraj, Sathish Devadoss, Annamalai Devadoss
BACKGROUND: Ankle arthrodesis has long been the traditional operative treatment for posttraumatic arthritis, rheumatoid arthritis, infection, neuromuscular conditions, and salvage of failed ankle arthroplasty. It remains the treatment of choice for patients in whom heavy and prolonged activity is anticipated. We present our short term followup study of functional outcome of patients who underwent transfibular ankle arthrodesis for arthritis of ankle due to various indications. MATERIALS AND METHODS: 29 transfibular ankle arthrodesis in 29 patients performed between April 2009 and April 2014 were included in this study...
January 2017: Indian Journal of Orthopaedics
https://www.readbyqxmd.com/read/28216195/golimumab-in-real-life-settings-2-years-drug-survival-and-predictors-of-clinical-outcomes-in-rheumatoid-arthritis-spondyloarthritis-and-psoriatic-arthritis
#13
Florenzo Iannone, Leonardo Santo, Maria Grazia Anelli, Romano Bucci, Angelo Semeraro, Laura Quarta, Francesca D'Onofrio, Antonio Marsico, Giorgio Carlino, Oriana Casilli, Fabio Cacciapaglia, Carmelo Zuccaro, Paola Chiara Falappone, Francesco Paolo Cantatore, Maurizio Muratore, Giovanni Lapadula
OBJECTIVES: To assess the drug survival of golimumab, and predictors thereof, in patients affected with rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA) in a prospective observational cohort. METHODS: This is a non-interventional, longitudinal study on RA, SpA, and PsA patients starting treatment with golimumab. Endpoints were the 2 years persistence rate of golimumab and predictors of therapy discontinuation. Drug retention was analyzed using Kaplan-Meier and Cox models...
January 18, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28216194/safety-of-resuming-biologic-dmards-in-patients-who-develop-tuberculosis-after-anti-tnf-treatment
#14
Soo-Kyung Cho, Dam Kim, Soyoung Won, Minkyung Han, Jiyoung Lee, Eun Jin Jang, Tae-Hyung Kim, Sang-Cheol Bae, Yoon-Kyoung Sung
OBJECTIVES: To estimate the incidence of tuberculosis (TB) in rheumatoid arthritis (RA) patients treated with tumor necrotizing factor inhibitor (TNFI) and evaluate the safety of resuming biologic disease-modifying anti-rheumatic drugs (DMARDs) in patients who developed TB after anti-TNF treatment. METHODS: We conducted an inception cohort study of RA patients in the Korean Healthcare Claims Database who started TNFI as the first biologic DMARD between January 2009 and December 2013...
January 18, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28215362/efficacy-and-safety-of-sirukumab-in-patients-with-active-rheumatoid-arthritis-refractory-to-anti-tnf-therapy-sirround-t-a-randomised-double-blind-placebo-controlled-parallel-group-multinational-phase-3-study
#15
Daniel Aletaha, Clifton O Bingham, Yoshiya Tanaka, Prasheen Agarwal, Regina Kurrasch, Paul P Tak, Sharon Popik
BACKGROUND: Sirukumab, a human monoclonal antibody that selectively binds to the interleukin-6 cytokine with high affinity, is under development for the treatment of rheumatoid arthritis and other diseases. We aimed to assess the efficacy and safety of sirukumab for rheumatoid arthritis in a phase 3 study (SIRROUND-T). METHODS: We did a randomised, double-blind, placebo-controlled, parallel-group, multicentre study at 183 hospitals and private rheumatology clinics in 20 countries (Argentina, Australia, Austria, Belgium, Canada, France, Germany, Italy, Japan, Lithuania, Mexico, Netherlands, Poland, Portugal, Russia, South Korea, Spain, Taiwan, UK, and USA)...
February 15, 2017: Lancet
https://www.readbyqxmd.com/read/28215100/targeting-baff-and-april-in-systemic-lupus-erythematosus-and-other-antibody-associated-diseases
#16
Eileen Samy, Stephen Wax, Bertrand Huard, Henry Hess, Pascal Schneider
The B cell-stimulating molecules, BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand), are critical factors in the maintenance of the B cell pool and humoral immunity. In addition, BAFF and APRIL are involved in the pathogenesis of a number of human autoimmune diseases, with elevated levels of these cytokines detected in the sera of patients with systemic lupus erythematosus (SLE), IgA nephropathy, Sjögren's syndrome, and rheumatoid arthritis. As such, both molecules are rational targets for new therapies in B cell-driven autoimmune diseases, and several inhibitors of BAFF or BAFF and APRIL together have been investigated in clinical trials...
January 2, 2017: International Reviews of Immunology
https://www.readbyqxmd.com/read/28214924/characteristics-and-outcomes-of-rheumatoid-arthritis-patients-who-started-biosimilar-infliximab
#17
Yoon-Kyoung Sung, Soo-Kyung Cho, Dam Kim, Soyoung Won, Chan-Bum Choi, So-Young Bang, Seung-Jae Hong, Hyoun Ah Kim, Eun-Mi Koh, Hye-Soon Lee, Chang-Hee Suh, Dae-Hyun Yoo, Sang-Cheol Bae
To compare the characteristics of rheumatoid arthritis (RA) patients receiving either biosimilar or originator infliximab and to identify the effectiveness and safety of biosimilar infliximab in RA patients in real-world practice. RA patients who started either biosimilar or originator infliximab were selected using the prospective biologic disease-modifying anti-rheumatic drugs (DMARDs) registry: BIOlogics Pharmacoepidemiologic StudY (BIOPSY). Baseline characteristics of the two groups were compared, and short-term treatment outcomes, including DAS28-ESR and HAQ-DI scores, were compared after initiation of biosimilar or originator infliximab...
February 18, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28214596/early-non-response-to-certolizumab-pegol-in-rheumatoid-arthritis-predicts-treatment-failure-at-one-year-data-from-a-randomised-phase-iii-clinical-trial
#18
Francis Berenbaum, Thao Pham, Pascal Claudepierre, Thibault de Chalus, Jean-Michel Joubert, Carine Saadoun, Lionel Riou França, Bruno Fautrel
OBJECTIVES: To compare different early clinical criteria of non-response determined at three months as predictors of clinical failure at one year in patients with rheumatoid arthritis starting therapy with certolizumab pegol. METHODS: Data were derived from a randomised Phase III clinical trial in patients with rheumatoid arthritis who failed to respond to methotrexate monotherapy. Patients included in this post-hoc analysis were treated with certolizumab pegol (400mg qd reduced to 200mg qd after one month) and with methotrexate...
February 15, 2017: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/28214456/total-wrist-arthroplasty
#19
Edward Lin, Nader Paksima
Total wrist arthroplasty (TWA), first performed in the late 19th Century, is still an infrequently used operation. It is most commonly indicated in patients with rheumatoid arthritis who have pan-carpal wrist involvement. It is an alternative to total wrist arthrodesis in patients who wish to preserve joint motion. Patients must lead a low-demand lifestyle and have failed non-operative measures. Complications are not insignificant and have been reported to be as high as 43%. Modern generation implants most often fail due to dislocation or loosening...
January 2017: Bulletin of the Hospital for Joint Diseases
https://www.readbyqxmd.com/read/28213794/selected-cytokine-pathways-in-rheumatoid-arthritis
#20
REVIEW
Mélissa Noack, Pierre Miossec
Rheumatoid arthritis (RA) is a chronic inflammatory disease leading to joint destruction. Cytokines play a key role in its pathogenesis. They contribute to the induction and maintenance of inflammation and thus provide therapeutic targets. Many cytokines are involved in RA, and this review focuses on a few critical ones: tumor necrosis factor (TNF), interleukin (IL)-6, IL-1, IL-17, and GM-CSF. TNF and IL-6 are both well-established targets in RA treatment, and new biologic agents are reaching the market. IL-1 represents a more complex cytokine as results in humans do not reach those in animal models...
February 17, 2017: Seminars in Immunopathology
keyword
keyword
24222
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"